Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy

被引：26

作者：

Hare, C. Bradley ^{[1
]}

Mellors, John ^{[2
]}

Krambrink, Amy ^{[3
]}

Su, Zhaohui ^{[3
]}

Skiest, Daniel ^{[4
]}

Margolis, David M. ^{[5
]}

Patel, Sheran S. ^{[2
]}

Barnas, Douglas ^{[2
]}

Frenkel, Lisa ^{[6
]}

Coombs, Robert W. ^{[6
]}

Aweeka, Francesca

Morse, Gene D. ^{[7
]}

Haas, David W. ^{[8
]}

Boltz, Valerie ^{[9
]}

Palmer, Sarah ^{[9
]}

Coffin, John ^{[9
]}

Havlir, Diane V.

机构：

[1] Univ Calif San Francisco, Dept Med, San Francisco Gen Hosp, San Francisco, CA 94110 USA

[2] Univ Pittsburgh, Pittsburgh, PA USA

[3] Harvard Univ, Sch Publ Hlth, Stat & Data Anal Ctr, Boston, MA 02115 USA

[4] Baystate Med Ctr, Springfield, MA USA

[5] Univ N Carolina, Chapel Hill, NC USA

[6] Univ Washington, Seattle, WA 98195 USA

[7] SUNY Buffalo, Buffalo, NY 14260 USA

[8] Vanderbilt Univ, Nashville, TN USA

[9] NCI, HIV Drug Resistance Program, Frederick, MD 21701 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2008年 / 47卷 / 03期

关键词：

D O I：

10.1086/589867

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Using standard and ultrasensitive techniques, we detected nonnucleoside reverse-transcriptase inhibitor-associated resistance mutations in 11 (20%) of 54 subjects who discontinued virologically suppressive nonnucleoside reverse-transcriptase inhibitor-containing antiretroviral therapy. Resistance was detected in 45% and 14% of subjects with a baseline human immunodeficiency virus type 1 RNA level of 51-400 copies/mL and <= 50 copies/mL, respectively. Mutations remained detectable for at least 48 weeks in some subjects.

引用

页码：421 / 424

页数：4

共 16 条

[1] Persistence of primary drug resistance among recently HIV-1 infected adults [J].

Barbour, JD ;

Hecht, FA ;

Wrin, T ;

Liegler, TJ ;

Ramstead, CA ;

Busch, MP ;

Segal, MR ;

Petropoulos, CJ ;

Grant, RM .

AIDS, 2004, 18 (12) :1683-1689

[2] Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study [J].

Cohen, Calvin J. ;

Colson, Amy E. ;

Sheble-Hall, Alexander G. ;

McLaughlin, Karen A. ;

Morse, Gene D. .

HIV CLINICAL TRIALS, 2007, 8 (01) :19-23

[3] A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection [J].

Dybul, M ;

Nies-Kraske, E ;

Dewar, R ;

Maldarelli, F ;

Hallahan, CW ;

Daucher, M ;

Piscitelli, SC ;

Ehler, L ;

Weigand, A ;

Palmer, S ;

Metcalf, JA ;

Davey, RT ;

Kress, DMR ;

Powers, A ;

Beck, I ;

Frenkel, L ;

Baseler, M ;

Coffin, J ;

Fauci, AS .

JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (11) :1974-1982

[4] Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: Effects on drug toxicity and on immunologic and virologic parameters [J].

Dybul, M ;

Nies-Kraske, E ;

Daucher, M ;

Hertogs, K ;

Hallahan, CW ;

Csako, G ;

Yoder, C ;

Ehler, L ;

Sklar, PA ;

Belson, M ;

Hidalgo, B ;

Metcalf, JA ;

Davey, RT ;

Kress, DMR ;

Powers, A ;

Fauci, AS .

JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (03) :388-396

[5]

Ellis GM, 2004, J CLIN MICROBIOL, V42, P3670, DOI [10.1128/JCM.42.8.3670-3674.2004, 10.1128/jcm.42.8.3670-3674.2004]

[6] Correlates of self-reported nonadherence to antiretroviral therapy in HIV-Infected patients - The Swiss HIV cohort study [J].

Glass, TR ;

De Geest, S ;

Weber, R ;

Vernazza, PL ;

Rickenbach, M ;

Furrer, H ;

Bernasconi, E ;

Cavassini, M ;

Hirschel, B ;

Battegay, M ;

Bucher, HC .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 41 (03) :385-392

[7] Long-term persistence of HIV with drug resistance after CD4 cell count-guided structured treatment interruption [J].

Halfon, P ;

Pénaranda, G ;

Khiri, H ;

Xerridat, B .

AIDS, 2005, 19 (15) :1713-1714

[8] Prevalence and predictive value of intermittent viremia with combination HIV therapy [J].

Havlir, DV ;

Bassett, R ;

Levitan, D ;

Gilbert, P ;

Tebas, P ;

Collier, AC ;

Hirsch, MS ;

Ignacio, C ;

Condra, J ;

Günthard, HF ;

Richman, DD ;

Wong, JK .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (02) :171-179

[9]

Johnson JA, 2006, ANTIVIR THER, V11, pS79

[10] Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia [J].

Karlsson, AC ;

Younger, SR ;

Martin, JN ;

Grossman, Z ;

Sinclair, E ;

Hunt, PW ;

Hagos, E ;

Nixon, DF ;

Deeks, SG .

AIDS, 2004, 18 (07) :981-989

← 1 2 →